ABSTRACT
Several studies demonstrate that the administration of exogenous mesenchymal stem cells (MSCs) contributes to the recovery of tissue injury in several organs such as heart, liver, brain, and pancreas. 1 Recently, the administration of in vitro expanded MSCs was shown to improve acute kidney injury (AKI). [2] [3] [4] [5] [6] [7] [8] Indeed, the infusion of MSCs protected and accelerated the recovery from AKI induced by cis-platinum, 3, 4, 9 glycerol, 5, 6 and ischemia-reperfusion injury. 7, 8 The mechanisms involved remain controversial. Some experiments based on bone marrow transplantation indicated that bone marrow-derived stem cells may contribute to repopulate the injured nephrons. 10, 11 MSCs were shown to localize within the injured kidneys when injected in mice with AKI. 3, 5, 6, 12 However, several reports indicate only a transient recruitment of MSCs in the renal vasculature without a direct incorporation within the regenerating tubules. 7, 8, 13 It was suggested that the transient presence of MSCs within the injured kidney may provide a paracrine support to the repair, which is mainly sustained by intrinsic epithelial cells surviving injury. 2, 14 Recently Bi et al. 9 showed that MSCs may protect the kidney from toxic injury by producing factors that limit apoptosis and enhance proliferation of the endogenous tubular cells, suggesting that the tubular engraftment of MSCs is not necessary for their beneficial effect.
Besides soluble factors, cell-derived microvesicles (MVs) were described as a new mechanism of cell-to-cell communication. 15 MVs are released by various cell types 15, 16 including stem cells and progenitors. 17, 18 MVs may interact with target cells by surface-expressed ligands, transfer surface receptors, deliver proteins, mRNA, and bioactive lipids. 15 Ratajczak et al. 17 showed that MVs derived from embryonic stem cells may reprogram hematopoietic progenitors by an mRNA-dependent mechanism. Recently, we demonstrated that MVs derived from human endothelial progenitor cells (EPCs) are able to trigger angiogenesis in human vascular endothelial cells by a horizontal transfer of mRNA. 18 In the present study, MVs obtained from human MSCs were characterized for the expression of surface molecules and for their mRNA content. Moreover, we evaluated whether administration of MSC-derived MVs in SCID mice with glycerol-induced AKI may favor functional and morphologic recovery. The effect of MVs was compared with that of MSC administration.
RESULTS

Characterization of MSC-Derived MVs
By cytofluorimetric analyses, MVs were detected mainly below the forward scatter signal corresponding to 1-m beads ( Figure 1A ). When determined by Zetasizer, the size of MVs ranged from 80 nm to 1 m, with a mean value of 135 nm. Transmission and scanning electron microscopy performed on purified MVs showed their spheroid morphology and confirmed their size ( Figure 2 A and B) . When electron microscopy was performed on MSCs cultured overnight in serum-free condition, structures resembling MVs were found within larger vesicles in the cytoplasm or dismissed from the cell surface (Figure 2 C, D, and E). Cytofluorimetric analyses showed the presence of several adhesion molecules known to be expressed on MSC plasma membrane such as CD44, CD29, ␣4-and ␣5 integrins, and CD73, but not ␣6-integrin ( Figure 1A ). In addition, MVs did not express HLA-class I at variance with the cells of origin.
Gene Array Analyses of MSC-Derived MVs
MVs contained mRNA that was submitted to microarray analysis, not to define the amount of mRNA, but only to define which transcripts were present. 18, 19 A total of 239 transcripts were found with this procedure; 132 were associated to Entrez Gene identifiers 20 by IPA 6.0 analysis (additional information: Table 1 ). This observation indicated that MVs shuttled a specific subset rather than a random sample of cellular mRNA. Several mRNA characteristic of mesenchymal cell lineages, such as neural, osteogenic, epithelial, and hematopoietic, were present (Table 1) . Moreover, MVs contained mRNA related to several cell functions involved in the control of transcription, cell proliferation, and immune regulation ( Table 2 ). Quantita- showing the size (with 1-, 2-and Ϫ4-m beads used as internal size standards) and the expression of CD44, CD29, ␣-4 integrin, ␣-5 integrin, CD73, ␣-6 integrin, and HLA-class I (thick lines) surface molecules. Dot lines indicate the isotypic controls. Ten different MV preparations were analyzed with similar results. In the CD44, CD29, ␣-4 integrin, ␣-5 integrin, and CD73 experiments, the Kolmogrov-Smirnov statistical analyses between relevant antibodies and the isotypic control was significant (P Ͻ 0.001). No significant expression of ␣-5-integrin and HLA class I was observed.
tive real time PCR confirmed the presence in MVs of genes randomly chosen from those detected by Microarray (POLR2E, SENP2/SUMO1, RBL1, CXCR7, LTA4H).
Incorporation of MSC-Derived MVs in Tubular Cells
MVs labeled with PKH26 dye were incorporated by cultured tubular epithelial cells (TECs) as shown by confocal microscopy and FACS analysis (Figure 3 A,B ). MV treatment with soluble hyaluronic acid and anti-CD44 and -CD29 blocking antibodies inhibited MV incorporation in TECs, whereas anti-␣4-integrin ( Figure 3 ) and ␣5-integrin (not shown) did not prevent MV internalization, suggesting that expression of CD44 and CD29 is critical for their internalization. Moreover, removal of surface molecules by trypsin treatment of MVs inhibited their incorporation in TECs, confirming the relevance of surface molecules in MV internalization (Figure 3 A,B) .
In Vitro Proliferative and Antiapoptotic Effects of MSC-Derived MVs
Incubation of TECs with different doses of MVs promoted cell proliferation compared with control cells incubated with vehicle alone ( Figure 4A ) and induced synthesis of hepatocyte growth factor (HGF) and macrophage-stimulating protein (MSP) ( Figure 4B ). In addition, incubation of TECs with MVs significantly inhibited apoptosis induced by serum deprivation ( Figure 4C ), vincristine, and cis-platinum ( Figure 4D ). MV treatment with soluble hyaluronic acid or trypsin, which inhibited MV incorporation, also inhibited the proliferative and antiapoptotic effects on TECs (Figure 4 A and B), suggesting that MV incorporation was required for their activity. However, when MVs were incubated with RNase that induced a complete degradation of the RNA shuttled by MVs, 18 the proliferation and the anti-apoptotic effects elicited by MVs were significantly reduced (Figure 4 A, C, and D). Figure 1B shows by FACS analyses that size and expression of surface adhesion molecules did not change in RNase-treated MVs. Moreover, internalization of RNase-treated MVs in TECs did not differ form that of untreated MVs ( Figure 3B ). DNase treatment was ineffective (not shown). RNase treatment of MVs did not interfere per se with TEC proliferation induced by the EGF (Figure 4A) . These results suggest that the MV biologic effects were mediated by the transfer of mRNA following MV internalization as described previously for EPC-derived MVs. 18 MV derived from human fibroblasts did not stimulate TEC proliferation nor inhibited apoptosis (data not shown).
In Vitro Evidence of De Novo Human Protein Expression in Murine TECs by MV-Mediated Horizontal Transfer of mRNA
We used as reporter genes POLR2E and SUMO-1, which were present in MVs derived from human MSCs. Human POLR2E and SUMO-1 were detected by real time PCR (RT-PCR) after 1 and 3 h of MV incubation with TECs ( Figure 5A ). The primers used did not recognize murine mRNA, as seen by negative RT-PCR in RNA extracted from control murine TECs. De novo cytoplasmic expression of human POLR2E protein and cytoplasmic and nuclear expression of SUMO-1 protein were detected in murine TECs after 24 h incubation with MVs ( Figure  5 B). Nuclear localization of both proteins was observed after 48 h ( Figure 5B ).
MSC-Derived MVs Protect Against Glycerol-Induced AKI
We compared the effect of human MSCs and MSC-derived MVs injected intravenously in glycerol-induced AKI in SCID mice ( Figure 6 ). Three days after glycerol injection, we observed a significant rise in blood urea nitrogen (BUN) and creatinine ( Figure 7A ) associated with a marked tubular epithelial injury, whereas control mice injected with saline alone displayed no histologic alterations (not shown). At day 3, MSCs or MSC-derived MVs were injected intravenously at doses of 75,000 cells (an amount of cells releasing approximately 15 g MVs overnight) or 15 g MV proteins, respectively . Mice were sacrificed at 4, 5, 8, and 15 d after induction of AKI ( Figure 6 ). The lesions observed in mice with AKI at days 4, 5, and 8 included tubular hyaline casts, vacuolization, and widespread necrosis of proximal and distal tubular epithelium ( Figure 7B ). Proximal tubules showed cytoplasmic vacuolization, swelling and disorganization of mitochondria, loss of brush border, and denudation of basal membrane (Figure 8 B and C). When mice were treated with MSCs or MVs, the tubular lesions were less severe at day 5 and almost absent at day 8 compared to those of mice treated with vehicle alone BASIC RESEARCH www.jasn.org ( Figure 7B ). The quantitative evaluation of casts and tubular necrosis at day 5 showed a significant reduction in MV-and MSC-treated mice in parallel with the reduction of BUN (Table 3). The recovery was complete at day 15 (not shown). By electron microscopy, tubular cells in MV-treated AKI mice showed a marked increase of mitochondria at day 5 that was decreased at day 8. In addition, the brush border was already restored at day 5, and the ultrastructure of tubules was almost indistinguishable from that of control mice without AKI (Figure 8 ). In addition, MSC-and MV-treated mice showed a significant reduction of both BUN and creatinine ( Figure 7A ). There was no significant difference between the treatment with MSCs and that of MVs ( Figure 7 , Table 3 ). In addition, MVs treated with sHA or trypsin did not significantly improve functional and morphologic injury compared with untreated AKI (Table 3 ). The specificity of MSC-derived MVs was also indicated by the absence of protective effects of MVs derived from human fibroblasts ( Table 3) . As shown in Figure 9 , MV treatment of mice with AKI significantly enhanced tubular cell proliferation compared to treatment with vehicle alone, as detected by PCNA-and 5-bromo-2Ј-deoxy-uridine (BrdU)-positive cells. The enhanced proliferation was detected 24 h (day 4 of AKI) and 48 h (day 5 of AKI) after MV administration and found to decrease thereafter. MSC treatment induced a comparable enhancement of cell proliferation ( Figure 9 ). The majority of PCNA-and BrdU-positive cells, seen in MVand in MSC-injected animals, were located in distal and proximal tubules. On the contrary, in untreated mice with AKI, proliferation was delayed as the number of PCNA-and BrdU positive cells increased only at day 8 when no further proliferation was detected in mice with AKI treated with MVs or MSCs. sHAtreated MVs as well as fibroblast-derived MVs did not significantly enhance proliferation ( Figure 9 A and B).
Evaluation of MV Localization After In Vivo Injection
When labeled MVs were injected, a significant accumulation in the kidney was observed at 6 h only in AKI mice ( Figure 10A ). After 1 h, MVs were detectable within the endothelial cells of large vessels and within the lumen of some injured tubules ( Figure  10B Trypsin-treated MVs did not localize in any of the examined organs ( Figure 10A ).
RNA Shuttled by MV Mediates MV-Induced Recovery of AKI
As shown in Figure 7 and in Table 3 , RNase treatment significantly reduced the recovery of BUN, creatinine, and tubular lesions that did not differ from those of untreated mice with AKI. Moreover at BASIC RESEARCH www.jasn.org day 8, in mice injected with MVs treated with RNase, the lesions persisted, with an increase in tubular casts and aspect of epithelial atrophy ( Figure 7B ). Tubular cell proliferation detected as BrdUor PCNA-positive cells in mice injected with RNase-treated MVs did not differ from that of untreated mice with AKI ( Figure 9 ).
In Vivo Evidence of De Novo Human Proteins Expression in the Kidney of AKI Mice Treated with Human MVs
RT-PCR for human POLR2E, used as reporter gene, confirmed the accumulation of MVs within the kidney of MV-treated AKI mice and not in normal controls ( Figure 11A ). Using antihuman POLR2E and SUMO-1 antibodies, the proteins were detected with a nuclear localization in tubules of mice with AKI treated with MV but not in untreated mice ( Figure 11B ). This observation suggests that specific mRNA shuttled by MVs can also be translated in vivo in proteins.
DISCUSSION
In the present study, we demonstrated that MVs derived from human MSCs are able to stimulate in vitro proliferation and apoptosis resistance of TECs and to accelerate in vivo the recovery of glycerol-induced AKI in SCID mice. The effect of Several studies demonstrated that the administration of bone marrow-derived MSCs may protect and reverse AKI in different experimental models. [2] [3] [4] [5] [6] [7] [8] [9] The low number of MSCs detectable within tubules after injury together with the increase in proliferating tubular cells throughout the kidney implies a trophic effect of MSCs on resident tubular cells that have survived injury, rather than a direct repopulation. 7, 8, 14 It was suggested that MSCs may exert their effects by a paracrine action on resident cells. 2, 7, 13, 21, 22 Recently, soluble factors were implicated in the MSC protective effect. 23 Bi et al. 9 showed that MSCs may protect the kidney from toxic injury by producing factors that limit apoptosis and enhance proliferation of the endogenous tubular cells, indicating that tubular engraftment of the MSCs is not necessary for their beneficial effect.
We demonstrated that intravenous administration of MVs derived from human MSCs has the same efficacy of MSCs on the functional and morphologic recovery of glycerol induced AKI in SCID mice. MVs are small vesicles released by cells that express the characteristic antigens of the cell from which they originate and carry membrane and cytoplasmic constituents. 15, 16 MVs may interact with target cells through specific receptor-ligand interactions and transfer receptors, proteins, and bioactive lipids. 16 Moreover, several studies showed that MVs may shuttle selected patterns of mRNA and proposed this as a new mechanism of genetic exchange between cells. [17] [18] [19] 24 In the present study, we demonstrate that MVs derived from MSCs may induce in vitro proliferation and apoptosis resistance in TECs. It was previously reported that MVs may express surface molecules characteristic of originating cells. 16 -18,25-27 We found that MSC-derived MVs expressed several adhesion molecules of MSCs such as CD44, CD29 (␤1-integrin), ␣4-and ␣5 integrins, and CD73, but not ␣6 integrin. Some of these molecules, namely CD44 and CD29, were found to be instrumental in MV internalization into TECs, as treatment with sHA or with anti-CD44 and anti-CD29 blocking antibodies prevented MV incorporation. Moreover, we found that the internalization of MVs was a requirement, but not the mechanism responsible, for their biologic activity. Indeed, RNase treatment almost completely abrogated the MV-induced in vitro proliferation and resistance to apoptosis of TECs.
The in vivo administration of MVs was found to accelerate the functional and morphologic recovery of AKI. These biologic BASIC RESEARCH www.jasn.org effects were specific for MSC-derived MVs as MVs obtained form fibroblasts were ineffective, and involved MV adhesion molecules as trypsin treatment abrogated MV accumulation in the kidney. MVs accumulated within the lumen of injured tubules, thus allowing an uptake from the apical part of tubular cells that survived injury. In addition, an uptake by endothelial cells was observed, suggesting that MVs may also reach the basolateral side of tubular cells via peritubular capillaries. Apart from inducing TEC proliferation, MVs may act by a mechanism of renal protection that limits the extent of injury. However, in the present experimental setting, MVs were administered at the peak of functional and morphologic alterations. 5, 6 As seen in vitro, pretreatment of MVs with RNase abrogated the protective effect of MVs. These results suggest that the transfer of small amounts of exogenous mRNA may stimulate tubular cell regeneration. Indeed, MVs derived from MSCs contained mRNA associated with the mesenchymal differentiative phenotype and with several cell functions involved in the control of transcription, proliferation, and cell immune regulation. Interestingly, as in EPC-derived MVs, MVs from MSCs carried a gene encoding the polymerase responsible for synthesizing mRNA in eukaryotes. 28 In vitro evidence for an effective horizontal transfer of mRNA was obtained by the presence of the human-specific mRNA for POLR2E and These studies open new research perspectives on the use of MVs to transfer RNA-based information from stem cells/precursors to target differentiated cells. An advantage of using MVs in regenerative medicine rather than the stem cells themselves is the avoidance of possible long-term pathologic differentiation of engrafted cells. 32 In conclusion, the mRNA transfer from MSCs to target cells through internalization of MVs contribute along with soluble factors to the regenerative effect of MSCs and could be exploited as a new therapeutic approach for regenerative medicine.
CONCISE METHODS
Isolation and Characterization of Human MSCs
Approval of the study was obtained from the Center for Molecular Biotechnology Institutional Review Board. Bone marrow cells were harvested from 13 different healthy donors with informed consent obtained in accordance with the Declaration of Helsinki, or obtained by Lonza (Basel, Switzerland). Bone marrow cells were layered on a Ficoll gradient (density: 1022 g/ml; Sigma-Aldrich, St. Louis, MO) and centrifuged at 1500 rpm for 30 min. The mononucleated cells were cultured in the presence of mesenchymal stem cells basal medium (MSCBM, Lonza). After 5 d of culture, the medium was changed. To expand the isolated cells, the adherent monolayer was detached by trypsin treatment for 5 min at 37°C, after 15 d for the first passage and every 7 d for successive passages. Cells were seeded at a density of 10,000 cells/cm 2 and used within the sixth passage.
At each passage, cells were counted and analyzed for immunophenotype by cytofluorimetric analysis and immunofluorescence. Cytofluorimetric analysis was performed as described 33 Indirect immunofluorescence was performed on MSCs using the following antibodies: mouse monoclonal anti-vimentin (Sigma) and rabbit polyclonal anti-von Willebrand factor (Dako Cytomation). Omission of the primary antibodies or substitution with nonimmune rabbit or mouse IgG were used as controls where appropriated. Alexa Fluor 488 anti-rabbit and anti-mouse Texas Red (Molecular Probes, Leiden, the Netherlands) were used as secondary antibodies.
MSCs preparations did not express hematopoietic markers like CD45, CD14, and CD34. They also did not express the costimulatory molecules (CD80, CD86, and CD40) and the endothelial markers (CD31, von Willebrand factor, KDR). All of the cell preparations at different passages of culture expressed the typical MSC markers: CD105, CD73, CD44, CD90, CD166, and CD146. They also expressed HLA class I. The adipogenic, osteogenic, and chondrogenic differentiation ability of MSC was determined as described previously. 34 Human fibroblasts, isolated from dermas as described 35 and used as control, were maintained in DMEM (Sigma) with 10% FCS (Euroclone, Wetherby, UK). 
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Isolation of MVs
MVs were obtained from supernatants of MSCs and of fibroblasts cultured in RPMI deprived of FCS and supplemented with 0.5% of BSA (Sigma). The viability of cells incubated overnight without serum was Ͼ 99% for MSCs and 85% Ϯ 4.3% for fibroblast as detected by trypan blue exclusion. No apoptotic cells were detected by TUNEL assay in MSCs, and 3.2% Ϯ 1.3% apoptotic cell were detected for fibroblast. After centrifugation at 2000 g for 20 min to remove debris, cell-free supernatants were centrifuged at 100,000 g (Beckman Coulter Optima L-90K ultracentrifuge) for 1 h at 4°C, washed in serum-free medium 199 containing N-2-hydroxyethylpiperazine-NЈ-2-ethanesulfonic acid (HEPES) 25mM (Sigma) and submitted to a second ultracentrifugation in the same conditions. 17, 18 To trace, in vitro and in vivo, MVs by fluorescence microscopy or FACS analysis, MVs from MSCs were labeled with the red fluorescence aliphatic chromophore intercalating into lipid bilayers PKH26 dye (Sigma). 36 After labeling, MVs were washed and ultracentrifuged at 100,000 g for 1 h at 4°C. MV pellets were suspended in medium 199, and the protein content was quantified by the Bradford method (BioRad, Hercules, CA). Endotoxin contamination of MVs was excluded by Limulus testing according to the manufacturer's instruction (Charles River Laboratories, Inc., Wilmington, MA), and MV were stored at Ϫ80°C. The morphologic analyses performed on MV suspension after staining with propidium iodide did not show the presence of apoptotic bodies.
In selected experiments, MVs from MSCs were treated with 1 U/ml RNase (Ambion Inc., Austin, TX) for 1 h at 37°C, the reaction was stopped by addition of 10 U/ml RNase inhibitor (Ambion Inc.) and MVs were washed by ultracentrifugation. 17, 18 The effectiveness of RNase treatment was evaluated after RNA extraction using TRIZOL reagent (Invitrogen, Carlsbad, CA) by spectrophotometer analysis of total extracted RNA (untreated: 1.3 Ϯ 0.2 g RNA/ mg protein MV; RNase treated: Ͻ0.2 g RNA/mg protein MV). In addition, RNA extracted from RNase-treated and untreated MVs was labeled by oligo dT driven retrotranscription and analyzed on 0.6% agarose gel to show the complete degradation of RNA by RNase treatment, as described previously. 18 As control, MVs were treated with 1 U/ml DNase (Ambion Inc.) for 1 h at 37°C.
FACS Analysis of MVs
The size of MVs was determined by cytofluorimetic analyses. The instrument was rinsed with particle-free rinse solution for 15 min to eliminate the background. The beads of different sizes (1, 2, 4, and 6 m, Molecular Probes, Invitrogen) were used as the size markers, and analysis was performed using a log scale for forward scatter and side scatter parameters. Moreover, the size of MV was evaluated by the Zetasizer Nano (Malvern Instruments, Malvern Worcestershire, UK) instrument, which permits discrimination of microparticles less than 1 m in diameter. Cytofluorimetric analysis was performed as described previously, 18,37 using the following FITC-or PE-conjugated antibodies: CD146, CD44 (Dako Cytomation), CD133 (Miltenyi Biotec), CD73, ICAM-1, ␣4-integrin, (Becton Dickinson), ␣v␤3-inte- grin, ␣5-integrin, ␣6-integrin (BioLegend, San Diego, CAUSA). FITC or PE mouse nonimmune isotypic IgG (Dako Cytomation) were used as control.
By cytofluorimetric analyses MVs, from human fibroblasts, were detected mainly below the forward scatter signal corresponding to 1-m beads (not shown); when determined by Zetasizer, the size of MVs was 180 nm (mean value). Cytofluorimetric analyses showed that MVs form human fibroblasts did not express adhesion molecules expressed on MVs derived from MSCs (CD44, CD29, CD73, ICAM-1, ␣4-integrin, ␣v␤3-integrin, ␣5-integrin, ␣6-integrin; not shown).
In vitro Isolation and Expansion of TECs
Kidneys were obtained from healthy female C57 mice. Kidneys were finely minced with scissors and then were forced through a 40-m pore filter (Becton Dickinson, San Jose, CA); the glomerular part and aggregated remained on the surface of filter while tubular cells were collected. After 2 washings in PBS (Lonza), the cell suspension was plated in a T25 flask (Becton Dickinson) in the presence of DMEM (Sigma) and 10% FCS. We changed media after 5 d to eliminate nonliving cells. TECs were characterized for their positive staining of cytokeratin, actin, alkaline phosphatase, aminopeptidase A, and megalin, and for negative staining for von Willebrand factor, CD45, nephrin, and desmin.
Incorporation of MVs in TECs
To study the capacity of MVs to incorporate into TECs, we incubated 50 g/ml of MVs, labeled with PKH-26 dye, for 30 min at 37°C. We studied the incorporation by FACS analyses and confocal microscopy.
To investigate the role of adhesion molecules expressed by MV surface in the incorporation in target cells, we preincubated MVs (15 min at 4°C) with blocking antibodies (1 g/ml) against the identified adhesion molecules anti-␣4-integrin (Biolegend), ␣5-integrin (Biolegend), CD29 (␤1-integrin) (Becton Dickinson), CD44 (Becton Dickinson) or with sHA (100 g/ml from Rooster comb; Sigma) before the incubation with the cells.
Immunofluorescence for Human Protein Expression in TECs
Indirect immunofluorescence was performed on TECs cultured on chamber slides (Nalgen Nunc International, Rochester, NY) and stimulated for 1 and 2 d in the presence of 30 g of different preparations of MVs. The cells were fixed in 4% paraformaldehyde containing 2% sucrose and permeabilized with HEPES-Triton X100 buffer (Sigma). The following antibodies were used: rabbit anti-human POLR2E (Abcam, Cambridge Science Park, UK) and rabbit anti-human Sumo-1 (AbCam). Omission of the primary antibodies and substitution with nonimmune rabbit IgG were used as controls. Alexa 
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Fluor 488 anti-rabbit (Molecular Probes) was used as secondary antibody. Confocal microscopy analysis was performed using a Zeiss LSM 5 Pascal Model Confocal Microscope (Carl Zeiss International, Germany). Hoechst 33258 dye (Sigma) was added for nuclear staining.
Cell Proliferation, Apoptosis Assays, and Release of HGF and MSP TECs were seeded at 4000 cells/well into 96-well plates in DMEM (Sigma) deprived of FCS. DNA synthesis was detected as incorporation of BrdU into the cellular DNA after 48 h of culture. Cells were then fixed with 0.5 M ethanol/HCl and incubated with nuclease to digest the DNA. BrdU incorporated into the DNA was detected using an anti-BrdU peroxidase-conjugated antibody and visualized with a soluble chromogenic substrate (Roche Applied Science, Mannheim, Germany). Optical density was measured with an ELISA reader at 405 nm. Apoptosis was evaluated using the TUNEL assay (ApopTag Oncor, Gaithersburg, MD) as described previously. 38 As apoptotic stimuli, we used serum deprivation or stimulation with 100 ng/ml of vincristine (Sigma) and 5 g/ml of cis-platinum (Sigma) in DMEM plus 3% FCS.
To evaluate the production of HGF and MSP, 1 ϫ 10 5 TECs were cultured with or without MV (30 g/ml) and, after 24 and 48 h of incubation, the supernatants were recovered and MSP-1and HGF production measured by ELISA (Raybiotech, Norcross GA) in accordance with manufacturer's instruction.
Gene Array Analysis
RNA extraction, Samples Labeling and Hybridization on BeadChips RNA was extracted from MVs using TRIZOL reagent (Invitrogen) following the procedure suggested by the manufacturer. Total RNA was quantified spectrophotometrically (Nanodrop ND-1000, Wilmington DE). cRNA was synthesized using three different quantities of total RNA (0.25 g, 0.5 g, and 1 g). cRNA synthesis and labeling was done using Illumina RNA Amplification Kit (Ambion) following the procedure suggested by manufacturer. Sentrix Human-6 Expression BeadChip hybridization, washing, and staining were also done as suggested by the manufacturer. Arrays were scanned on Illumina BeadStation 500 (Illumina, San Diego, CA). Transcripts present in the MVs were defined as those characterized by a positive linear relation between the transcript signal detected by the microarray analysis and the amount of total RNA hybridized. 18 
Microarray Data Analysis
The analysis was done hybridizing arrays with labeled-cRNA produced using three different concentrations of total RNA extracted from two independent preparations of MVs. BeadChip array data quality control was performed using Illumina BeadStudio software, version 1.3.1.5. Transcript average intensity signals were calculated with BeadStudio without background correction. Raw data were analyzed using Bioconductor. 39 Average transcript intensities were log 2 transformed and normalized by the Loess method. 20 A simple statistical linear model 18 was used to identify transcript signals linearly correlated to the increment of total RNA concentration used to prepare cRNA. In equation (1), y ij is the observed expression level for transcript i in sample j (j ϭ 1,. . . ,6), is the average expression level of transcript I, and ␤ RNA represents the effect of total RNA concentration on the expression level of transcript i. represents random error for transcript i and sample j, and it is assumed to be independent for each transcript and sample, and normally distributed with mean 0 and variance
Transcripts characterized by a model with P Յ 0.05, r 2 Ն 0.8, and a positive slope were selected (239).
Transcripts annotation and data mining were performed using IPA 4.0 software (www.ingenuity.com). Microarray data were deposited on GEO database (http://www.ncbi.nlm.nih.gov/projects/geo/) as geo accession GSE12243. 
Quantitative Real Time PCR
Quantitative real time PCR was performed as described previously. 40 Quantitative real-time PCR was performed on total RNA extracted from cells used to produce MVs and from an MV preparation different from those used for microarray analysis. Cell cDNA was used to evaluate primers efficiency. The primers used for real time PCR are shown in Table 4 . First-strand cDNA was produced from total RNA using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA). Briefly, 200 to 400 ng mRNA, 2 l RT buffer, 0.8 l dNTP mixture, 2 l RT random primers, 1 l MultiScribe reverse transcriptase, and 4.2 l nuclease-free water were used for each cDNA synthesis. After the reverse transcription, cDNA was stored at Ϫ20°C. Twenty microliters of RT-PCR mix, containing 1X SYBR GREEN PCR Master Mix (Applied Biosystems), 100 nM of each primer, and 0 l, 1 l, and 2 l of MV cDNA, were assembled using a 48-well StepOne Real Time System (Applied Biosystems). Negative cDNA controls (no cDNA) were cycled in parallel with each run.
Reverse Transcriptase PCR (RT-PCR)
Total RNA extracted from TECs or from kidneys of SCID mice was submitted to RT-PCR 41 using the primer for human POLR2E and SUMO-1 reported in Table 4 . Bands of the expected size (90 bp) were detected in a 4% agarose gel after electrophoresis. cDNA from a preparation of human bone marrow MSC was used as positive control.
SCID Mice Model of AKI
Studies were approved and conducted in accordance with the National Institute of Health Guide for the Care and Use of Laboratory Animals. As described previously, 5, 6, 30 a model of rhabdomyolisisinduced AKI was performed in male SCID mice (7 to 8 wk old) (Charles River Laboratories), by intramuscular injection with hypertonic glycerol (8 ml/kg body weight of 50% glycerol solution) into the inferior hind limbs ( Figure 6 ). Intramuscular injection of glycerol induces myolisis and hemolysis causing toxic and ischemic tubular injury. 5, 6 On day 3 after glycerol administration, mice received an intravenous injection into the tail vein of 15 g of MVs from MSCs treated with sHA, or trypsin or RNase-MVs, or 15 g of MVs from human fibroblasts, or 75,000 BM-MSCs in 150 l saline, or saline alone. The following groups were studied: group 1, AKI group; group 2, AKI plus 15 Kidney tissues were processed for histology, immunohistochemistry, immunofluorescence and transmission electron microscopy.
Morphologic Studies
For renal histology 5-m-thick paraffin kidney sections were routinely stained with hematoxylin and eosin (Merck, Darmstadt, Germany). Luminal hyaline casts and cell lose (denudation of tubular basement membrane) were assessed in nonoverlapping fields (up to 28 for each section) using a 40x objective (high power filed, HPF). Number of casts and tubular profiles showing necrosis were recorded in a single-blind fashion. 4 Transmission electron microscopy was performed on Karnovsky's-fixed, osmium tetraoxide-postfixed tissues and embedded in epoxy resin according to standard procedures. 42 Ultrathin sections were stained with uranyl acetate and lead citrate and were examined with a Jeol JEM 1010 electron microscope. Transmission electron microscopy was also performed on MVs or on cultured MSCs releasing MVs processed as described above. For scanning electron microscopy MVs were fixed in Karnovsky fixative, dehydrated in alcohol, dried on glass surface and coated with gold by sputter coating. The specimens were examined in a scanning Jeol T300 electron microscope. Images were obtained via secondary electron at a working distance of 15 to 25 mm and an accelerating voltage of 20 to 25 kV.
Immunohistochemistry for detection of proliferation of tubular cells was performed as described previously. 9 Kidney sections were subjected to antigen retrieval, and slides were blocked and labeled with 1:25 dilution of monoclonal anti BrdU antibody (Dako Cytomation) or 1:400 of monoclonal anti-PCNA (Santa Cruz Biotechnology, Santa Cruz CA). Immunoperoxidase staining was performed using 1:300 dilution of anti-mouse HRP (Pierce, Rockford IL). Scoring for BrdU-and PCNA -positive cells was carried out by counting the number of positive nuclei per field in 10 randomly chosen sections of kidney cortex using 40x magnification. Confocal microscopy analysis was performed on frozen sections for localization of PKH26-labeled MVs in different murine organs and for detection of specific human proteins POLR2E and SUMO-1. Section were blocked and labeled with rabbit anti-human POLR2E (Abcam) (1:300 dilution) or rabbit antihuman Sumo-1 (Abcam) (1:300 dilution) or rabbit anti Laminin (Sigma) (1:100 dilution) or rabbit anti von Willebrand factor (Dako Cytomation) (1:100 dilution). Omission of the primary antibodies or substitution with nonimmune rabbit IgG were used as controls. Alexa Fluor 488 anti-rabbit (Molecular Probes) was used as secondary antibody. POLR2E  5Ј-GCTCTGGAAAATCCGCAAGA-3Ј  5Ј-TCCTCCAGGGTCTGGTCAAG-3Ј  SENP2/SUMO1  5Ј-AAATAAGATCGACCAATGCAAGTG-3Ј  5Ј-TCACAGTCCAGGAGTGAAGTAATCA-3Ј  RBL1  5Ј-GAGAACTGGGTCCTTAGCACTATTTT-3Ј  5Ј-ACACGTCCATATCTTCCTTCGTAAC-3Ј  CXCR7  5Ј-TGGGTTACAAAGCTGCCATCTA-3Ј  5Ј-TGGCTGTGCTGTGCGCT-3Ј  LTA4H 5Ј-CCTATCGCTTTGAGCAAAAATCA-3Ј 5Ј-GTGTTCCTTCCCAGAAGTCTGTTC-3Ј
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Plasma BUN and Creatinine
Blood samples for measurement of BUN and plasma creatinine were collected before and 3, 4, 5, 8 and 15 d after glycerol-induced AKI. Creatinine concentrations were determined using a Beckman Creatinine Analyzer II (Beckman Instruments, Inc., Fullerton, CA). 6 Creatinine levels that exceeded 0.3 mg/dl were considered abnormal (normal range in our laboratory: 0.1 to 0.3 mg/dl). BUN was assessed in heparinized blood using a Beckman Synchrotron CX9 automated chemistry analyzer (Beckman).
Spectrofluorimetric Detection of MVs in Different Tissues after In Vivo Injection
To evaluate the amount of MVs in different murine organs, we injected intravenously AKI or healthy mice with 100 g of PKH-26 labeled MVs treated or not with trypsin. Mice were sacrificed after 15 min, 1, 3, and 6 h and liver, lungs, kidneys, and blood were recovered. The content of PKH-26 in different samples was measured after lipid extraction with chloroform-isopropyl alcohol (1:1 vol/vol) and 0.125% SDS (Sigma) of homogenized tissues (Tissue Ruptor, Quiagen) or plasma. The fluorescence intensity of PKH-26-containing lipid extracts were measured with Fluoromax-4 spectrofluorimeter (Horiba Jobin Yvon_Edison NJ). Excitation wavelength was positioned at 550 nm; emission wavelength was set at 567 nm. Calibration values for maximum and minimum were obtained using 20 g/ml and decreasing concentration until 1 g/ml of lipid extracts of PKH26-labeled MV. Each lipid sample (from different organs and plasma) was analyzed in PBS (Sigma) containing 0.1% triton X100 (Sigma). As negative control, we measured fluorescence intensity in lipids extracted from untreated mice. Data were expressed as micrograms per gram of dry tissue or micrograms per microliter plasma.
Statistical Analysis
Statistical analysis was performed by using the t test, ANOVA with Newmann-Keuls, or ANOVA with Dunnet's multicomparison tests, as appropriate. A p value of Ͻ0.05 was considered significant.
